THE ULTIMATE BIOPHARMA DEALMAKERS REPORT FOR ALLIANCES AND M&AS 

Since the beginning of July 2016 through the end of the second quarter of 2019, biopharma companies have inked more than 500 alliances where potential deal value of more than $50 million was disclosed. 

In this second edition, Chris Morrison expands on his analysis of game-changing deals with the addition of the most recent mega-deals as well as the aggregate effects of all alliances and acquisitions.

Download this in-depth report for the details of these game-changing deals and what they indicate for the future of the biopharma industry.
 

PAGE 11

APPENDIX 

PAGE 1

SEC 1: ALLIANCE TRENDS 

PAGE 1

SEC 1: ALLIANCE TRENDS

PAGE 7

SEC 2: M&A TRENDS 

WHAT'S INSIDE

DOWNLOAD THE REPORT 

Chris Morrison has covered the biopharmaceutical industry for 20 years as a writer and editor for several industry publications. He is a former editor of In Vivo: The Business and Medicine Report and "The Pink Sheet" where he focused on trends in biopharmaceutical finance, business development, and research and development. Chris contributes to a variety of publications, including In Vivo, Datamonitor, Nature Biotechnology, and Nature Reviews Drug Discovery. He holds a bachelor’s degree in neurobiology and behavior from Cornell University and a master’s in science journalism from New York University.

THE AUTHOR

All Rights Reserved. Forward ® 2019
EBD Group, 3150 Pio Pico Drive, Suite 201, Carlsbad, CA 92008